Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
met-enkephalin
- Development stage
- Unknown
- Lead developer
- University of Missouri-Columbia
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Opioid Growth Factor (OGF), chemically known as met-enkephalin ([Met5]-enkephalin), is an endogenous pentapeptide biologic being investigated by the University of Missouri-Columbia for the treatment of unresectable hepatocellular carcinoma (HCC) in patients with cirrhosis. OGF functions as a negative growth regulator by binding to the Opioid Growth Factor Receptor (OGFr), which forms an endogenous growth-regulating pathway. This interaction exerts a dose-dependent, reversible, and receptor-mediated inhibitory action on cancer cell proliferation, specifically through the induction of the cyclin-dependent kinase inhibitory pathway. The drug has been evaluated in Phase I clinical trials (such as NCT00706576) where it was administered via intravenous infusion to assess safety, toxicity, and pharmacokinetics in patients with advanced liver disease and underlying cirrhosis.
- Other names
- Opioid Growth Factor[Met5]-enkephalinOGFMet-enkephalin
02
Targets
OGFR (Opioid growth factor receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on met-enkephalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on met-enkephalin.